Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 11/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988415 | 0.77 | BDKRB1 (0.34) | BDKRB1 | |
| SCHEMBL4981015 | 0.72 | CTSA (0.41) | CTSAFFAR4BDKRB1 | |
| SCHEMBL4983690 | 0.71 | DGAT1 (0.39) | — | |
| SCHEMBL4981006 | 0.69 | CTSA (0.41) | CTSAFFAR4BDKRB1 | |
| SCHEMBL12999417 | 0.67 | CA12 (0.41) | CTSALRRK2CA12CA1CA2 | |
| SCHEMBL29353186 | 0.66 | ALOX5AP (0.45) | CTSAFFAR4 | |
| SCHEMBL6607015 | 0.66 | ALOX5AP (0.45) | CTSAFFAR4 | |
| SCHEMBL4922112 | 0.66 | S1PR1 (0.41) | CTSAABCB1 | |
| SCHEMBL28757562 | 0.66 | RORC (0.39) | CTSAFFAR4BDKRB1LRRK2CA12 | |
| SCHEMBL23362825 | 0.65 | LRRK2 (0.38) | CTSAFFAR4BDKRB1LRRK2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332499-B2 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO., INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | MERCK SHARP & DOHME CORP. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247229-A1 | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides | BDKRB1, BDKRB2, CNR2 | CTSA 967/4885FFAR4 401/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.